Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Rachel Brightwell"'
Publikováno v:
Gynecologic Oncology Reports, Vol 14, Iss C, Pp 6-8 (2015)
Externí odkaz:
https://doaj.org/article/b1b8359228bc421a8f83bd874e49b2fd
Autor:
Mohd Arshad, Kevin H. Eng, K.S. Grzankowski, Hongbin Chen, Shashikant Lele, Rachel Brightwell, Kunle Odunsi
Publikováno v:
Gynecologic Oncology. 143:393-397
Objectives The CD47 "don't eat me" signal allows tumor immune evasion. We tested the association of CD47 expression with outcomes in EOC. Methods CD47 expression was examined within the TCGA database for ovarian carcinoma. For validation, IHC was per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b166e73e1fc68919ca24c3e99abf34
https://doi.org/10.1016/j.ygyno.2016.08.325
https://doi.org/10.1016/j.ygyno.2016.08.325
Publikováno v:
Gynecologic Oncology Reports, Vol 14, Iss C, Pp 6-8 (2015)
Gynecologic Oncology Reports
Gynecologic Oncology Reports
Highlights • Treatment of sex-cord stromal tumors with carboplatin and taxane is both feasible and safe. • FOXL2 mutations account for approximately 50% of these tumors. • Carboplatin and taxane may afford a favorable outcome.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d174031d553fb018fb30a042baf2f2e
http://www.sciencedirect.com/science/article/pii/S2352578915000570
http://www.sciencedirect.com/science/article/pii/S2352578915000570
Publikováno v:
Gynecologic Oncology Reports
Gynecologic Oncology Reports, Vol 11, Iss C, Pp 10-12 (2015)
Gynecologic Oncology Reports, Vol 11, Iss C, Pp 10-12 (2015)
Highlights • Malignant peritoneal mesothelioma is a rare aggressive tumor with approximately 400 new cases annually in the US. • In optimal cytoreduction HIPEC is the standard treatment. • In suboptimal cytoreduction IV cisplatin and pemetrexed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266a69543500c09b87f29651ec32d5b6
Autor:
Rikki Cannioto, Nonna Kolomeyevskaya, Grace Friel, J. Brian Szender, Kirsten B. Moysich, Gary Zirpoli, K.S. Grzankowski, Albina N. Minlikeeva, Rachel Brightwell
ObjectivesPrognostic risk factors influencing survival in patients with epithelial ovarian cancer (EOC) include tumor stage, grade, histologic subtype, debulking, and platinum status. Little is known about the impact of hormonal milieu and reproducti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4a1ccff8ac08a3640dea28487741cb6
https://europepmc.org/articles/PMC4665090/
https://europepmc.org/articles/PMC4665090/
Autor:
Shashikant Lele, Rachel Brightwell
Publikováno v:
Uterine Cancer ISBN: 9788132218913
Type II endometrial carcinomas, accounting for 10–20 % of women diagnosed, are typically higher grade, diagnosed at a later stage of the disease, and with precursor lesions rarely identified. Type II endometrial carcinomas include uterine papillary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::086f13f8abd63c5c3ccd4f4b8f49aac2
https://doi.org/10.1007/978-81-322-1892-0_23
https://doi.org/10.1007/978-81-322-1892-0_23
Autor:
J.B. Szender, Rachel Brightwell, Peter J. Frederick, C.L. Spring-Robinson, K.S. Grzankowski, Kunle Odunsi, Shashikant Lele
Publikováno v:
Gynecologic Oncology. 141:59-60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc67bac62600e763f7ebdaab541d03b4
https://doi.org/10.1016/j.ygyno.2016.04.176
https://doi.org/10.1016/j.ygyno.2016.04.176
Autor:
Harlan Robins, Takemasa Tsuji, Kevin H. Eng, Junko Matsuzaki, Erika Lindsley, Song Liu, Anthony Miliotto, Ryan O. Emerson, Kunle Odunsi, Cindy Desmarais, Sacha Gnjatic, Julie Rubinstein, Rachel Brightwell, Jianmin Wang
Publikováno v:
Journal for Immunotherapy of Cancer
Background The prognostic significance of the number of tumorinfiltrating T cells has been demonstrated for many tumor types. In contrast, the significance of the tumorinfiltrating T cell clonality, which reflects the preferential infiltration or exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2714a55cdcdd01753c89c302ab2d73e4
https://doi.org/10.1186/2051-1426-1-s1-p64
https://doi.org/10.1186/2051-1426-1-s1-p64
Publikováno v:
Gynecologic Oncology. 141:197
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1748d6d33b78689c0edc83f60aa968d9
https://doi.org/10.1016/j.ygyno.2016.04.509
https://doi.org/10.1016/j.ygyno.2016.04.509
Publikováno v:
Gynecologic Oncology. 141:136
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f5d21a79cb8d7895372a066ae72933e
https://doi.org/10.1016/j.ygyno.2016.04.359
https://doi.org/10.1016/j.ygyno.2016.04.359